24
Participants
Start Date
June 27, 2013
Primary Completion Date
July 8, 2016
Study Completion Date
March 16, 2017
Dose D1 of interleukin-2
subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
placebo
subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
Dose D2 of Interleukin-2
subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
Dose D3 of interleukin-2
subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
CIC pédiatrique - CHU de Necker, Paris
Service d'endocrinologie pédiatrique - CHU de Necker, Paris
CIC 9202 CHU Rober Débré, Paris
Service d'endocrinologie Diabétologie pédiatrique CHU Robert Débré, Paris
Service d'Endocrinologie Pédiatrique, Le Kremlin-Bicêtre
Service de Pédiatrie - CHU de Nîmes, Nîmes
Assistance Publique - Hôpitaux de Paris
OTHER